News

The IND acceptance allows the company to start an open-label Phase I trial designed to evaluate the safety, pharmacokinetics and clinical activity of KB003 in previously treated CMML

FX006 is a new, non-opioid, sustained-release, intra-articular (IA) (within the joint) formulation of triamcinolone acetonide (TCA) designed to treat patients with moderate to severe osteoarthritis (OA) pain of

Mogamulizumab is a new, humanized mAb directed against CC chemokine receptor type 4 (CCR4). Opdivo is a PD-1 immune checkpoint inhibitor that has received approval from the US

The fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide, a GLP-1 RA, demonstrated statistically superior reduction in HbA1c (average blood glucose over the previous three months) compared

Narcan Nasal Spray has been granted Fast Track Designation by the FDA. Narcan Nasal Spray was developed in collaboration with the National Institutes on Drug Abuse (NIDA). There

The core expertise of PRC Clinical is focused on Clinical Trial Management, Clinical Site Monitoring, and Clinical Payment Services. The CSSi LifeSciences and PRC Clinical partnership equips both

"Important goals of pharmacotherapy for ulcerative colitis are to induce and maintain remission while improving the patient’s quality of life, and, based on the results from our Phase

Roxane is a well-established US specialty generics company with a highly differentiated product portfolio and best-in-class R&D capabilities. Under the terms of the acquisition, on closing of the

ZS-9 is an insoluble, non-absorbed zirconium silicate with a three-dimensional crystalline lattice structure that was designed to preferentially trap potassium ions. The potassium selectivity of ZS-9 allows high